ALS/MND Unit of the University Hospital of Bellvitge – Miquel Valls Foundation The Motor Neurone Disease Unit of the University Hospital of Bellvitge in collaboration with Miquel Valls Foundation provides multidisciplinary and specialized care for people with ALS or other Motor Neurone Diseases (more than150 persons attended for year); database of patients; collaboration and promotion of clinical trials and ALS research, together with INP (Institute of Neuropathology of HUB) and IDIBELL (Institute of Biomedical Research of Bellvitge); Biobank Idibell (DNA and other samples of ALS patients).
Miquel Valls Foundation is a non lucrative organization that aims to improve the quality of life of people suffering from ALS and offer support to their families, as well as fighting the disease by promoting research in ALS. The Foundation provides assistance for people with ALS and families through support and advice by socials workers, occupational therapists and psychologist (more than 350 families attended every year in Catalonia); supply of specialized equipment (Bank of assistive technology products); coordination of medical and social ALS care; promotion and collaboration in ALS research. Contact: mpovedano@bellvitgehospital.cat
| ALS/MND Unit of the University Hospital of Bellvitge – Miquel Valls Foundation Centres | |
|---|---|
| Foundation year | 2005 |
| Director | Prof. M. Povedano |
| Principal investigator | Prof. M. Povedano |
| Contact information | |
|---|---|
| Address | Feixa Llarga S/N(08907) |
| Contact | M. Povedano |
| Phone | 937665969 |
| Fax | 937697014 |
| ela@miquelvallsfoundation.org | |
| Website | Visit the website |
Publications
- Amyotroph Lateral Scler Frontotemporal Degener. 2016 Apr-May;17(3-4):221-7. Epub 2016 Jan 4. Cognitive impairment in ALS patients and validation of the Spanish version of the ALS-CBS test. Turon-Sans J1, Gascon-Bayarri J1, Reñé R1, Rico I1, Gámez C2, Paipa A1, Povedano M1.
- Chest. 2005 Jun;127(6):2132-8. Survival in amyotrophic lateral sclerosis with home mechanical ventilation: the impact of systematic respiratory assessment and bulbar involvement. Farrero E1, Prats E, Povedano M, Martinez-Matos JA, Manresa F, Escarrabill J.
- Rev Port Pneumol. 2014 Jul-Aug;20(4):188-93. doi: 10.1016/j.rppneu.2014.03.001. Epub 2014 Apr 29. Place of death in patients with amyotrophic lateral sclerosis. Escarrabill J1, Vianello A2, Farrero E3, Ambrosino N4, Martínez Llorens J5, Vitacca M6.
Restricted information
| Serving population | |
|---|---|
| Serving population | 1.000.0000 or more |
| Patient resources | |
|---|---|
| Population based register | No |
| Clinic based register | Yes |
| Geographically matched controls | No |
| Number of skin samples | 60 |
Banks
| Type | ALS Patients | Controls | Other |
|---|---|---|---|
| DNA Bank | 200 | 0 | 0 |
| CSF Bank | 130 | 0 | 0 |
| Serum Bank | 100 | 0 | 0 |
| Research activities | |
|---|---|
| Clinical management research | Yes |
| Neuro epidemiology | Yes |
| Neuro physiology | Yes |
| Neuro imaging | No |
| Neuro psychology | Yes |
| Neuro pathology | Yes |
| Genomics | No |
| Transcriptomics | No |
| Metabolomics | Yes |
Clinical Trials - Industry sponsored
| Name | Type | Patients |
|---|---|---|
| Phase 3 Study of Dexpramipexole in ALS (EMPOW) | Phase 3 Study of Dexpramipexole in ALS (EMPOW) | 15 |
| Efficacy and Safety of Plasma Exchange With A | Efficacy and Safety of Plasma Exchange With A | 10 |
| Efficacy and Safety of Masitinib in Combinati | Efficacy and Safety of Masitinib in Combinati | 30 |
Clinical Trials - Investigator initiated
There are no clinical trials for this centre